Abbott has strengthened its digital health ecosystem by adding Laralab, a Munich-based AI cardiac imaging company, to its portfolio.
The news was shared by Sandra Lesenfants, Senior Vice President of Abbott’s Structural Heart division, who announced the acquisition on LinkedIn.
“We’re thrilled to welcome Laralab’s talented team to Abbott and together expand the reach of heart.ai — an innovative, cloud-based cardiac imaging technology that empowers clinicians in planning structural heart interventions.”
While Abbott — one of the world’s largest medtech companies — did not disclose the financial details of the deal, the move underscores its continued focus on digital innovation in cardiac care.
Laralab, known for its AI-powered imaging solutions in interventional cardiology, received FDA 510(k) clearance in April for its platform, making it the first and only fully automated AI platform for comprehensive CT analysis across key areas of structural heart anatomy — including the mitral, tricuspid, and aortic valves, as well as cardiac chambers.
Built on deep learning technology, Laralab’s platform delivers high-precision anatomical assessments from standard CT data, enabling clinicians to make informed decisions and plan transcatheter procedures such as TAVR, TMVR, and TTVR.
“Bringing Laralab to Abbott reinforces our commitment to deliver digital tools and devices that optimize procedures, support better outcomes, and deliver a streamlined experience for providers throughout the care journey,” Lesenfants added.
Also Read
